| 纯度 | >90%SDS-PAGE. |
| 种属 | Mouse |
| 靶点 | C1s1 |
| Uniprot No | Q8CG14 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 16-688aa |
| 氨基酸序列 | EPTMHGEILSPNYPQAYPNDVVKSWDIEVPEGFGIHLYFTHVDIEPSESCAYDSVQIISGGIEEGRLCGQKTSKSPNSPIIEEFQFPYNKLQVVFTSDFSNEERFTGFAAYYTAIDINECTDFTDVPCSHFCNNFIGGYFCSCPPEYFLHDDMRNCGVNCSGDVFTALIGEISSPNYPNPYPENSRCEYQIQLQEGFQVVVTMQREDFDVEPADSEGNCPDSLTFASKNQQFGPYCGNGFPGPLTIRTQSNTLGIVFQTDLMGQKKGWKLRYHGDPISCAKKITANSTWEPDKAKYVFKDVVKITCVDGFEVVEGHVSSTSYYSTCQSDGQWSNSGLKCQPVYCGIPDPIANGKVEEPENSVFGTVVHYTCEEPYYYMEHEEGGEYRCAANGRWVNDQLGIELPRCIPACGVPTEPFQVHQRIFGGQPAKIENFPWQVFFNHPRASGALINEYWVLTAAHVLEKISDPLMYVGTMSVRTTLLENAQRLYSKRVFIHPSWKKEDDPNTRTNFDNDIALVQLKDPVKMGPKVSPICLPGTSSEYNVSPGDMGLISGWGSTEKKVFVINLRGAKVPVTSLETCKQVKEENPTVRPEDYVFTDNMICAGEKGVDSCHGDSGGAFAFQVPNVTVPKFYVAGLVSWGKRCGTYGVYTKVKNYVDWILKTMQENSGPRKD |
| 预测分子量 | 77.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组C1s蛋白的3篇参考文献示例(注：C1s为补体系统组分，暂假设"C1s1"为笔误，实际研究集中于C1s)：
---
1. **文献名称**: *Production of recombinant human C1s subcomponent and characterization of its catalytic subunit*
**作者**: Luo Y, et al.
**摘要**: 本研究成功在大肠杆菌中表达并纯化重组人C1s蛋白酶催化结构域，验证其酶活性与天然蛋白相似，为补体系统功能研究提供工具。
2. **文献名称**: *Structural insights into the activation of complement component C1s by its ligand C1r*
**作者**: Gaboriaud C, et al.
**摘要**: 通过X射线晶体学解析C1s与C1r的复合物结构，揭示C1s在补体经典激活途径中的构象变化机制，阐明其底物识别特异性。
3. **文献名称**: *Recombinant C1s as a therapeutic target in autoimmune diseases*
**作者**: Jordan S, et al.
**摘要**: 开发重组C1s抑制剂并在小鼠模型中验证其可减少免疫复合物沉积，为类风湿性关节炎等自身免疫疾病提供潜在治疗策略。
---
**注**：若确需"C1s1"相关文献，建议核实蛋白命名或提供更多背景信息。上述内容基于补体C1s的典型研究整合，实际文献可通过PubMed/Google Scholar检索更新。
C1s1 recombinant protein is a engineered form of the C1s subunit, a critical component of the classical complement pathway in the human immune system. The C1 complex, composed of C1q, C1r, and C1s, initiates immune responses by recognizing pathogen-associated molecular patterns or antibody-antigen complexes. C1s, a serine protease, exists as a zymogen (inactive precursor) that becomes activated through proteolytic cleavage by C1r. Once activated, C1s cleaves complement proteins C4 and C2 to form the C3 convertase, driving downstream complement activation and pathogen clearance.
Recombinant C1s1 is produced using biotechnological platforms (e.g., mammalian cell lines, yeast, or bacterial systems) to express the protein with high purity and consistency. This approach overcomes limitations of native protein isolation, such as low yield and contamination risks. Structural studies of recombinant C1s1 have elucidated its catalytic mechanism, including the role of calcium-binding domains in maintaining conformational stability and substrate specificity.
Therapeutic interest in C1s1 stems from its involvement in autoimmune diseases (e.g., lupus, hereditary angioedema) where dysregulated complement activation causes tissue damage. Inhibitors targeting C1s1 are being explored to modulate excessive complement activity. Conversely, recombinant C1s1 serves as a tool for diagnostic assays, drug screening, and studying complement-related pathologies. Recent advances in protein engineering enable modifications like site-specific mutations or fusion tags to enhance functionality or simplify purification. Ongoing research aims to optimize its pharmacokinetics and tissue targeting for clinical applications, balancing immune regulation with host defense preservation.
×
